The prognostic value of tumor mutation burden in EGFR -mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base

Tumor mutation burden (TMB) is novel biomarker of promising predict value in prediction of immune checkpoint inhibitors (ICPis) in non-small cell lung cancer (NSCLC). However, the distribution of TMB in epidermal growth factor receptor ( )-mutant advanced lung adenocarcinoma (LUAD) patients and the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic disease 2019-11, Vol.11 (11), p.4507-4515
Main Authors: Jiao, Xiao-Dong, He, Xi, Qin, Bao-Dong, Liu, Ke, Wu, Ying, Liu, Jun, Hou, Ting, Zang, Yuan-Sheng
Format: Article
Language:English
Subjects:
Original
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor mutation burden (TMB) is novel biomarker of promising predict value in prediction of immune checkpoint inhibitors (ICPis) in non-small cell lung cancer (NSCLC). However, the distribution of TMB in epidermal growth factor receptor ( )-mutant advanced lung adenocarcinoma (LUAD) patients and the impact on overall survival (OS) time are not well demonstrated. Information regarding gene mutations and patients' survival time in advanced LUAD was downloaded from The Cancer Genome Atlas (TCGA) database. The diversity of TMB in different -mutant types was observed and the predicted value of TMB for OS as well as other co-mutations were analyzed. The diversity of TMB was also observed in another Chinese cohort of advanced LUAD patients. The median TMB values of wild-type, other types of mutations, exon 19 deletions and L858R were 6.12, 5.66, 3.77 and 4.72, differences between wild-type and sensitive mutations (exon 19 deletion or L858R) were significant (P
ISSN:2072-1439
2077-6624
DOI:10.21037/jtd.2019.11.04